{"nctId":"NCT00440531","briefTitle":"Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)","startDateStruct":{"date":"2006-11"},"conditions":["Hepatitis B"],"count":540,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: Modified Process Hepatitis B Vaccine (Experimental)"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: ENGERIX-B™ (currently licensed product)"]}],"interventions":[{"name":"Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)","otherNames":[]},{"name":"Comparator: Modified Process Hepatitis B Vaccine (Experimental)","otherNames":[]},{"name":"Comparator: ENGERIX-B™ (currently licensed product)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy male and female older adults greater than or equal to 50 years of age\n\nExclusion Criteria:\n\n* Any adult with a history of previous hepatitis B infection\n* A history of vaccination with any hepatitis B vaccine\n* Recent (\\<72 hours) history of febrile illness (oral temperature =37.8ºC/=100.0ºF)\n* Known or suspected hypersensitivity to any component of RECOMBIVAX HB™ or ENGERIX-B™ (e.g., aluminum, yeast)\n* Recent administration (within 3 months prior to first injection with the study vaccine) of hepatitis B immune globulin (HBIG), serum immune globulin, or any other blood-derived product\n* Receipt of licensed inactivated vaccines within 14 days prior to first injection with the study vaccine\n* Receipt of licensed live virus vaccines within the 30 days prior to injection with the study vaccine\n* Receipt of investigational drugs or other investigational vaccines within 3 months prior to first injection with the study vaccine\n* Known or suspected impairment of immunologic function or recent use of immunomodulatory medications (e.g., systemic corticosteroids). Does not include topical and inhaled steroids\n* Pregnant women, nursing mothers, and women planning to become pregnant within the study period\n* Any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Seroresponders to the Modified Process Hepatitis B Vaccine and RECOMBIVAX HB™ (Currently Licensed Vaccine)","description":"The number of participants as measured by the seroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Day 1 (prior to the first vaccination) and at Month 7 (1 month after the third vaccination).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Seroresponders to ENGERIX-B™ (Currently Licensed Vaccine)","description":"The number of participants as measured by the seroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Day 1 (prior to the first vaccination) and at Month 7 (1 month after the third vaccination).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null}]}]}]},{"type":"SECONDARY","title":"The Total Number of Participants With One or More Injection-site Adverse Experiences","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"115","spread":null},{"groupId":"OG002","value":"107","spread":null}]}]}]},{"type":"SECONDARY","title":"The Total Number of Participants With a Maximum Temperature >=100.0F/37.8C","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Total Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}}